Vorinostat, a histone deacetylase inhibitor, has activity against high-grade glioma in preclinical studies and may work synergistically with cytotoxic chemotherapy. In this phase I trial, we evaluated escalating doses of vorinostat in combination with temozolomide. We show that vorinostat can be administered safely on days 1-7 and 15-21 of every 28-day cycle in doses up to 500 mg daily when combined with temozolomide 150 mg/m2/day x 5 days in 28-day cycles and in doses up to 400 mg daily when combined with temozolomide 150 mg/m2/day x 5 days for the first 28-day cycle and 200 mg/m2/day x 5 days for the subsequent 28-day cycles. Pharmacokinetic analysis revealed no significant interactions between vorinostat and temozolomide. Based on these results a phase I/II trial of vorinostat in combination with temozolomide and radiotherapy for newly-diagnosed glioblastoma is in progress.
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Research. 
INTRODUCTION
Histone proteins organize DNA into nucleosomes, which are regular repeating structures of chromatin (1) . The acetylation status of histones alters chromatin structure and is regulated by two classes of enzymes, histone deacetylases (HDACs) and histone acetyltransferases (HATs). This acetylation affects the regulation of gene expression by rendering certain genes accessible to transcriptional machinery. There is increasing evidence that HDAC or HAT activity is altered in many cancers, including gliomas.
HDAC inhibitors (HDACi) can induce growth arrest, differentiation and/or apoptosis of tumor cells in vitro and in vivo by altering the transcription of a small number of genes and represent a promising novel therapeutic approach to cancer (1, 2) .
Vorinostat is a small molecule inhibitor of HDAC that binds directly in the enzyme's active site in the presence of a zinc ion and is approved by the United States Federal Drug Administration (FDA) for use in patients with cutaneous T-cell lymphoma who have progressive, persistent, or recurrent disease on or following two systemic therapies.
Vorinostat has activity against high-grade glioma (HGG) lines in vitro and in vivo and appears to pass through the blood brain barrier (3) (4) (5) (6) . In a phase II study of recurrent glioblastoma (GBM), vorinostat was generally well tolerated and demonstrated modest single agent activity with a six-month progression-free survival rate (PFS6) of 15.2% (7).
In addition, tumor samples of GBM patients who received vorinostat prior to surgery indicated that this agent was able to penetrate tumors and inhibited histone acetylation (7).
Research. Acetylation of key lysine residues in core histones leads to a more relaxed chromatin configuration. Therefore, HDAC inhibitors, by allowing acetylation, may provide cytotoxic chemotherapy with enhanced access to DNA resulting in synergistic activity (2) . Temozolomide (TMZ) is an alkylating agent with efficacy in HGG; as established by the phase III clinical trial demonstrating that the addition of TMZ to radiation extends overall survival in patients with newly diagnosed GBM compared to radiation alone (8, 9) . Treatment of U87 glioma cell lines with vorinostat and temozolomide results in a supra-additive effect on growth inhibition (10) . Therefore, the North American Brain Tumor Consortium (NABTC) conducted a phase I study to investigate the combination of vorinostat with temozolomide in patients with HGG. 
MATERIALS AND METHODS

This
Patient Selection
Research. Patients were eligible for the study if they had histologically proven intracranial HGG (glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma not otherwise specified), were 18 years or older, and had a Karnofsky performance status (KPS) ≥ 60, adequate bone marrow function (WBC ≥ 3,000/μl, ANC ≥ 1,500/mm 3 , platelet count ≥ 100,000/mm 3 , and hemoglobin ≥ 10 gm/dl), adequate liver function (SGOT and bilirubin < 2 times the upper limit of normal), adequate renal function (creatinine < 1.5 mg/dL), and were ≥ 3 weeks from completion of radiotherapy. Patients who had previously progressed on TMZ as well as patients who were taking valproic acid (another HDAC inhibitor) within 2 weeks prior to enrollment were excluded. For Part 1, patients with either stable disease after radiotherapy (with or without concurrent TMZ) or following progression on radiotherapy alone (i.e. no concurrent TMZ) were eligible. Any number of prior relapses was allowed. For Part 2, only patients with stable disease after radiotherapy were eligible and the only prior therapies permitted were concomitant TMZ with radiotherapy or radiotherapy alone. Central pathology review was performed by KA.
Study Design
The primary objectives of the study were to define the maximum tolerated dose (MTD) and to characterize the safety profile of vorinostat in combination with TMZ in patients A standard 3+3 dose escalation design was used for both parts of the study and MTD was defined as the dose at which fewer than one-third of patients experienced a DLT to vorinostat in combination with TMZ. In Part 1, the MTD was based on assessment of were enrolled at the MTD to further characterize the toxicity profile.
Pharmacokinetic Evaluation
Sample Collection
In Cycle 1, blood (6 mL) was collected from a peripheral vein into anticoagulant-free (vorinostat) or heparinized (TMZ) tubes before treatment and 1, 2, 3, 4, 6 and 8 hours after the first dose on day 1. Blood samples were also drawn before the first dose on day 2 and day 8. In Part 2 of the study, samples were also collected in cycle 2 using a similar schedule. Blood collected for determination of vorinostat was allowed to clot at 4°C for 20-30 minutes Blood collected for determination of TMZ was stabilized with 1.0 N HCl.
Blood was separated by centrifugation into serum (vorinostat) or plasma (TMZ), transferred into plastic cryotubes, and stored at -70°C until analysis.
Temozolomide Assay Methodology
TMZ was assayed using high-performance liquid chromatography with UV detection as previously described (11) .
Vorinostat Assay Methodology
Vorinostat concentrations were measured by a validated liquid chromatographyelectrospray ionization tandem mass spectrometry method [A] as described by Galanis et al (12) .
Correlative Studies
Blood samples for acetylation status of histones in peripheral blood mononuclear cells and H4 in various samples were examined by western blot analysis as previously reported (13) .
Statistical Analysis
Baseline characteristics were summarized across all enrolled patients. Safety variables were summarized by descriptive statistics. Adverse events were described in terms of Normalized OD values of histone H3 and H4 were plotted as a vertical scatter plot and the differences in the means of the values were compared for significance using a twoway ANOVA (for cycle 1 samples) or a paired t-test (for cycle 2 and for cycle 1 baseline versus 24 hour sample comparison).
RESULTS
Patient Characteristics
Fifty-nine eligible patients were enrolled (Table 1) . Pathology included 39 GBM, 2 gliosarcoma, 13 AA, 1 AO, and 4 AOA. Median age was 51 (range 25-81) and median KPS was 90 (range 60-100). Thirty-four were male and 25 were female.
MTD and Safety
The MTD of vorinostat on days 1-14 of every 28 days in combination with TMZ 150 mg/m 2 /day for 5 days every 28 days was 300 mg daily (Group A). However, the exposure of vorinostat achieved with this dose was low based on PK analysis. To increase the exposure, a schedule of vorinostat administered on days 1-7 and 15-21 of every 28 day cycle in combination with TMZ was examined (Group B). On this schedule, the MTD of Table 3 lists the grade 3 or higher adverse events related to combination therapy according to dose levels. The most common serious adverse events considered possibly, probably, or definitely related to vorinostat in combination with TMZ were fatigue (15%), lymphopenia (8%), thrombocytopenia (8%), and thromboembolic event (5%).
Pharmacokinetics
Pharmacokinetic analysis of TMZ was performed on 16 patients enrolled in the study (Supplementary Table A) . Peak plasma concentrations were achieved 1.95 ± 0.91 hrs after the oral dose, and the mean TMZ half-life was 1.95 ± 1.95 hrs. These pharmacokinetic findings are comparable to a comparison trial of single agent TMZ in advanced cancers (14) suggesting no significant interaction with vorinostat. 
Correlative Studies
Samples were available from 33 patients for assessment of histone H3 and H4 acetylation for the baseline and at least 3 consecutive post-treatment samples for each patient for cycle 1. Vorinostat treatment resulted in hyperacetylation of both proteins in these samples with the highest average levels being seen at the 2 hour time point as shown in Figure 1A although the highest values in the individual patients occurred at either the 1
hour or 2 hour time point. Of note, there was an apparent decrease in mean of acetylation levels at 24 hours compared to the baseline levels but this was not statistically significant (p=0.35). A similar appearance of histone hyperacetylation was seen during cycle 2 with the post-treatment levels being significantly higher than pretreatment baseline. These findings are consistent with the expected effects of vorinostat in PBMC.
Clinical Outcomes
The median number of cycles of combination therapy was 6 (Table 5) 
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